Dendreon's Provenge: Interview With Head, Large Urology Group Practice [View article]
Hi Ted, thanks for all your work on DNDN. As I am not a scientist, I have tended to stay away from development-stage biotech for the simple reason that others have far more insight into handicapping companies' prospects than I do. Add to that the perception that the FDA is a "rigged game", and the risk reward profile (for me) is usually unfavorable. As a punt, I have usually invested only in companies controlled by R.J. Kirk, who I know has a great record of developing and selling novel technologies (ex-CLDA; now HALO and ZIOP.)
But I do like cheap stocks with good prospects, and so bought some DNDN and HGSI late in 2011. Your articles have been a primary source of information on DNDN. So please keep up the great work. Do you have an opinion on KERX ahead of the unblinding of perifosine trials?
Dendreon: Following Up On Market Mania [View article]
Very helpful article...thanks! I bought a "starter position" at year end for a bounce...certainly was not disappointed in that bounce. Could you provide some additional insight on how you value DNDN to get $30-40$ target? Thanks.
Dendreon's Provenge: Interview With Head, Large Urology Group Practice [View article]
But I do like cheap stocks with good prospects, and so bought some DNDN and HGSI late in 2011. Your articles have been a primary source of information on DNDN. So please keep up the great work. Do you have an opinion on KERX ahead of the unblinding of perifosine trials?
Dendreon: Following Up On Market Mania [View article]